We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Alliance for Infectious Disease Treatments

By Biotechdaily staff writers
Posted on 29 May 2002
A collaboration to develop new antibody products to treat infectious diseases has been announced by two Danish companies: Genmab A/S (Copenhagen; www.genmab.com) and Ace BioSciences (Odense; www.acebiosciences). More...
Under their agreement, the companies will share development costs and revenues.

The alliance will combine Ace BioSciences's expertise in finding novel infectious disease targets with Genmab's broad antibody development capabilities and preclinical tools to generate and characterize fully human antibodies. Ace BioSciences will provide commercially promising targets, while Genmab will use its antibody technology to create and develop new therapeutics. Genmab creates and develops fully human antibodies for the treatment of disease. Ace BioSciences's focus on infectious diseases is based on a broad biotechnology platform that integrates biology and analytical chemistry. The company's protein interaction technology is used to discover protein targets in a wide range of infectious bacteria and fungi.

"We are very excited by this alliance with Genmab because the company's expertise and proven track record in developing therapeutic antibodies positions Ace BioSciences on a fast track to develop treatments for infectious diseases,” said Ejvind Mortz, Ph.D., CEO of Ace BioSciences.




Related Links:
Genmab
Ace BioSciences

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Steam Sterilizer
Hi Vac II Line
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.